Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Public ClinicalTrials.gov record NCT00888173. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study identification
- NCT ID
- NCT00888173
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
- Endometrial Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- Endometrial Mucinous Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Squamous Cell Carcinoma
- Endometrial Transitional Cell Carcinoma
- Endometrial Undifferentiated Carcinoma
- Recurrent Uterine Corpus Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 6, 2009 (Actual)
- Primary completion
- Jul 16, 2016 (Actual)
- Completion
- Jul 16, 2016 (Actual)
- Last update posted
- Dec 6, 2017
2009 – 2016
United States locations
- U.S. sites
- 35
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Cancer Center - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06050 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Saint Vincent Hospital and Health Care Center | Indianapolis | Indiana | 46260 | — |
| McFarland Clinic PC-William R Bliss Cancer Center | Ames | Iowa | 50010 | — |
| Iowa Methodist Medical Center | Des Moines | Iowa | 50309 | — |
| Iowa-Wide Oncology Research Coalition NCORP | Des Moines | Iowa | 50309 | — |
| Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa | 50309 | — |
| Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa | 50314 | — |
| Mercy Medical Center - Des Moines | Des Moines | Iowa | 50314 | — |
| Iowa Lutheran Hospital | Des Moines | Iowa | 50316 | — |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Spectrum Health at Butterworth Campus | Grand Rapids | Michigan | 49503 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| North Shore University Hospital | Manhasset | New York | 11030 | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11040 | — |
| North Shore-LIJ Health System/Center for Advanced Medicine | New Hyde Park | New York | 11040 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa | Oklahoma | 74146 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | — |
| Carilion Clinic Gynecological Oncology | Roanoke | Virginia | 24016 | — |
| Pacific Gynecology Specialists | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Swedish Medical Center-First Hill | Seattle | Washington | 98122-4307 | — |
| Northwest Hospital | Seattle | Washington | 98133 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| Green Bay Oncology at Saint Vincent Hospital | Green Bay | Wisconsin | 54301-3526 | — |
| Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin | 54301 | — |
| Green Bay Oncology Limited at Saint Mary's Hospital | Green Bay | Wisconsin | 54303 | — |
| Gundersen Lutheran Medical Center | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00888173, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00888173 live on ClinicalTrials.gov.